Amyloid Antibodies for the Treatment of Alzheimer's
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.626 alerts
Get alerted when Policy 5.01.626 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This policy governs coverage and prior authorization for Kisunla, Leqembi, and Leqembi Iqlik for adults with Alzheimer's disease. It defines medical-necessity criteria, documentation, dosing and quantity limits, authorization duration, investigational uses, and applicable billing codes.
Policy Summary
PayerPremera Bluecross
PolicyAmyloid Antibodies for the Treatment of Alzheimer's
Policy CodePolicy 5.01.626
Change TypeModified
Effective DateSeptember 1, 2026
Last ReviewAug 11, 2026
Next Review DateN/A
Key ActionSubmit documentation showing that applicable drug-specific criteria are met when requesting initial authorization for Kisunla, Leqembi, or Leqembi Iqlik.
The September 2026 interim review updated the Leqembi Iqlik criteria by removing the requirement for 18 months of prior intravenous Leqembi therapy.
The July 2026 annual review removed reference to non-formulary exception reviews and removed BCBSA Reference Policy 5.01.538 because that policy had been discontinued.
The May 2025 annual review removed Aduhelm and HCPCS code J0172 after the manufacturer discontinued the product.
Aduhelm (aducanumab) was removed from the policy because the manufacturer discontinued the product.
Coverage criteria were added for Kisunla (donanemab-azbt) for treatment of Alzheimer's disease.
Leqembi (lecanemab-irmb) coverage criteria were updated to include dosing of 10 mg/kg once every four weeks after 18 months of initial therapy.
Leqembi Iqlik (lecanemab-irmb) criteria were updated by removing the requirement for 18 months of prior intravenous Leqembi therapy.
The HCPCS descriptor for J0174 was updated.
3
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Amyloid antibody products addressed
18+Minimum age for covered treatment
12 monthsInitial authorization period
12 monthsBaseline brain MRI timing
InvestigationalUnoutlined uses
Medical Necessity and Coverage Criteria
Initial therapy: Kisunla
Kisunla may be considered medically necessary when ALL of the following are met.
Kisunla eligibility
Clinical eligibility
Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.Baseline MRI within 12 months
Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.
Treatment administration requirements: Kisunla is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, and the maintenance dose is limited to 1,400 mg every 4 weeks.1,400 mg every 4 weeks
Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.
Initial therapy: Leqembi IV
Leqembi IV may be considered medically necessary when ALL of the following are met.
Leqembi IV eligibility
Clinical eligibility
Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.
Initial therapy: Leqembi Iqlik
Leqembi Iqlik may be considered medically necessary when ALL of the following are met.
Leqembi Iqlik eligibility
Clinical eligibility
Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.
Continuation therapy
Reauthorization may be approved for up to 12 months when ALL of the following are met.
Continuation therapy: The applicable drug-specific policy coverage criteria continue to be met; medical records demonstrate a continued positive clinical response to therapy; and a brain MRI is completed to check for radiographically observed ARIA when warranted.Up to 12 months
Applies to Kisunla, Leqembi, and Leqembi Iqlik.
Coverage is not available when cognitive impairment is attributable to another medical condition rather than Alzheimer’s disease. Examples include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to a mood disorder, or untreated thyroid disease.
The requested amyloid antibody must not be used in combination with another monoclonal antibody for the treatment of Alzheimer’s disease. This exclusion applies to combinations involving Kisunla, Leqembi, or Leqembi Iqlik.
This medical policy does not apply to Medicare Advantage. Coverage for Medicare Advantage members is subject to the applicable plan and coverage rules.
UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
CDR Memory Box Score
Qualifying scoreAt least 0.5
AssessmentCDR Memory Box score
Use
Authorization and Documentation Requirements
Prior Authorization
Initial Authorization Required
Prior authorization is required before initiating Kisunla (donanemab-azbt), Leqembi (lecanemab-irmb), or Leqembi Iqlik (lecanemab-irmb). Initial authorization may be approved for up to 12 months when the applicable medical-necessity criteria are met.
Applies to Kisunla, Leqembi IV, and Leqembi Iqlik SC.
Prior Authorization
Reauthorization
Reauthorization may be approved for up to 12 months when the drug-specific coverage criteria continue to be met, the individual demonstrates a positive clinical response, and required monitoring is documented.
Submit evidence of continued eligibility and clinical response.
Complete brain MRI to evaluate for radiographically observed amyloid-related imaging abnormalities (ARIA) when warranted.
Clinical Background
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive and functional decline. Its principal pathologic hallmarks are amyloid plaques and tau neurofibrillary tangles.
Amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarker testing can identify beta-amyloid pathology. This policy addresses amyloid beta-directed antibody treatment for adults with Alzheimer’s disease who have mild cognitive impairment or mild Alzheimer’s disease dementia, including treatment with Kisunla and Leqembi products.
Terms and Abbreviations
ARIA-E
TermARIA-E
MeaningAmyloid-related imaging abnormalities with edema or effusion
Policy contextA potential risk associated with amyloid antibody treatment that must be discussed
ARIA-H
TermARIA-H
MeaningAmyloid-related imaging abnormalities with hemosiderin deposition
Policy contextA potential risk associated with amyloid antibody treatment that must be discussed
Drug-Specific Initial Therapy
Kisunla initial therapy
Kisunla may be considered medically necessary when ALL of the drug-specific criteria are met.
Kisunla: The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, and receives no more than 1,400 mg every 4 weeks.18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 1,400 mg every 4 weeks
Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.
Leqembi IV initial therapy
Leqembi IV may be considered medically necessary when ALL of the drug-specific criteria are met.
Reauthorization Criteria
Reauthorization
Reauthorization may be approved for up to 12 months when ALL of the following are met.
Reauthorization: The drug-specific policy coverage criteria remain met; the individual continues to show a positive clinical response to therapy; and a brain MRI is completed to check for radiographically observed ARIA when warranted.Up to 12 months
Applies to Kisunla, Leqembi, and Leqembi Iqlik.
Leqembi Iqlik Quantity Limits
Leqembi Iqlik 250 mg/1.25 mL Autoinjector
Product and strengthLeqembi Iqlik 250 mg/1.25 mL autoinjector
Quantity limit8 autoinjectors per 28 days
Dose schedule500 mg once every week
Leqembi Iqlik 360 mg/1.5 mL Autoinjector
Product and strengthLeqembi Iqlik 360 mg/1.5 mL autoinjector
Quantity limit4 autoinjectors per 28 days
Dose schedule500 mg once every week
Policy Summary
PayerPremera Bluecross
PolicyAmyloid Antibodies for the Treatment of Alzheimer's
Policy CodePolicy 5.01.626
Change TypeModified
Effective DateSeptember 1, 2026
Last ReviewAug 11, 2026
Next Review DateN/A
Key ActionSubmit documentation showing that applicable drug-specific criteria are met when requesting initial authorization for Kisunla, Leqembi, or Leqembi Iqlik.
Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.
Treatment administration requirements: Leqembi is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, and dosing is limited to 10 mg/kg once every two weeks for 18 months, followed after 18 months by 10 mg/kg once every 2 weeks or once every 4 weeks.10 mg/kg every 2 weeks for 18 months; thereafter every 2 or 4 weeks
Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.
Baseline MRI within 12 months
Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.
Treatment administration requirements: Leqembi Iqlik is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, the dose is limited to 500 mg once every week, and quantity is limited to 8 autoinjectors per 28 days for the 250 mg/1.25 mL autoinjector or 4 autoinjectors per 28 days for the 360 mg/1.5 mL autoinjector.500 mg once weekly; 8 or 4 autoinjectors per 28 days depending on strength
Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.
Documents mild cognitive impairment or mild Alzheimer's disease dementia
Mini-Mental Status Examination
Qualifying scoreAt least 22
AssessmentMini-Mental Status Examination (MMSE)
UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
Montreal Cognitive Assessment
Qualifying scoreAt least 17
AssessmentMontreal Cognitive Assessment (MoCA)
UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
Baseline Brain MRI
Required timingCompleted within 12 months prior to initiating treatment
Imaging studyBaseline brain magnetic resonance imaging (MRI)
Applies toKisunla, Leqembi IV, and Leqembi Iqlik initial therapy
Leqembi IV Dose
Initial dose10 mg/kg once every two weeks for 18 months
After 18 months10 mg/kg once every 2 weeks or once every 4 weeks
ProductLeqembi (lecanemab-irmb) IV
Leqembi Iqlik Dose
Dose500 mg once every week
RouteSubcutaneous administration
ProductLeqembi Iqlik (lecanemab-irmb)
Kisunla Maintenance Dose
Maintenance dose1,400 mg every 4 weeks
ProductKisunla (donanemab-azbt)
Administration requirementMaintenance dose is limited to 1,400 mg every 4 weeks
Kisunla Low/Medium Tau Population
Tau populationLow/medium tau
Tau PET SUVR rangeAt least 1.10 and no more than 1.46
Assessment methodTau PET imaging with flortaucipir
Kisunla Combined Tau Population
Tau populationCombined low/medium plus high tau population
Tau PET SUVR thresholdGreater than 1.46
Assessment methodTau PET imaging with flortaucipir
Documentation Required
Medical Records and Office Notes
Submit medical records and office visit notes documenting that medical-necessity criteria are met for the requested therapy.
Office visit notes must include the diagnosis, relevant history, physical evaluation, and medication history.
Documentation Required
Clinical Eligibility Evidence
Document the clinical evidence supporting eligibility for treatment with Kisunla, Leqembi, or Leqembi Iqlik.
Individual is aged 18 years or older and has a diagnosis of Alzheimer's disease.
Cognitive testing documents mild cognitive impairment or mild Alzheimer's disease dementia by at least one of the following: Global Clinical Dementia Rating (CDR) score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination (MMSE) score of at least 22; or Montreal Cognitive Assessment (MoCA) score of at least 17.
Documented beta-amyloid deposition is demonstrated by a positive amyloid PET scan or CSF biomarker abnormalities suggestive of beta-amyloid accumulation in the brain.
Chart notes document ApoE ε4 status testing and discussion of potential risks, including ARIA-E and ARIA-H.
Baseline brain MRI was completed within 12 months before treatment initiation.
Documentation supports that cognitive impairment is not due to another medical condition.
Documentation Required
Reauthorization Documentation
For renewal, submit records showing that the individual remains eligible under the drug-specific policy criteria and continues to respond positively to therapy.
Provide medical records demonstrating continued positive clinical response.
Document brain MRI monitoring for radiographically observed ARIA when warranted.
Continue to document that applicable coverage criteria remain met.
Denial Risk
Clinical Eligibility Not Met
Coverage is not supported when required eligibility evidence is absent or when the individual does not meet the policy's clinical requirements.
Individual is younger than 18 years or does not have a diagnosis of Alzheimer's disease.
Cognitive testing does not indicate mild cognitive impairment or mild Alzheimer's disease dementia, or the required score documentation is absent.
Beta-amyloid deposition is not documented by qualifying amyloid PET or CSF biomarker evidence.
ApoE ε4 testing, risk discussion, or baseline brain MRI within 12 months before initiation is not documented.
Cognitive impairment is attributable to another condition, including dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to a mood disorder, or untreated thyroid disease.
Denial Risk
Combination, Specialist, and Dosing Requirements
The requested therapy must satisfy the policy's combination-use, specialist-prescribing, dosing, and quantity requirements.
Do not use Kisunla in combination with Leqembi or Leqembi Iqlik, or use Leqembi or Leqembi Iqlik in combination with another monoclonal antibody for Alzheimer's disease.
Treatment must be prescribed by or provided in consultation with a dementia specialist, such as a neurologist, geriatric psychiatrist, neuropsychiatrist, or geriatrician.
Kisunla maintenance dose: 1,400 mg every 4 weeks.
Leqembi IV dose: 10 mg/kg once every 2 weeks for 18 months; after 18 months, 10 mg/kg once every 2 weeks or once every 4 weeks.
Leqembi Iqlik dose: 500 mg once every week; quantity is limited to 8 250-mg/1.25-mL autoinjectors or 4 360-mg/1.5-mL autoinjectors per 28 days.
Denial Risk
Unoutlined Use
All other uses of Kisunla, Leqembi, and Leqembi Iqlik for conditions not outlined in the policy are considered investigational and are not covered under these criteria.
Kisunla (donanemab-azbt)
Leqembi (lecanemab-irmb)
Leqembi Iqlik (lecanemab-irmb)
MCI
AbbreviationMCI
MeaningMild cognitive impairment
Policy contextAn early Alzheimer's disease stage represented in the treatment population
A/T/N Biomarker Classification
ClassificationA/T/N biomarker classification
A, T, and NA: aggregated amyloid-beta; T: aggregated tau; N: neurodegeneration or neuronal injury
Examples of measuresAmyloid PET or CSF Aβ for A; tau PET or phosphorylated tau for T; MRI, FDG PET, or CSF total tau for N
CSF
AbbreviationCSF
MeaningCerebrospinal fluid
Policy useMay be used for biomarker testing to document beta-amyloid accumulation
MCI
AbbreviationMCI
MeaningMild cognitive impairment
Clinical contextA cognitive stage within the Alzheimer's continuum
MRI
AbbreviationMRI
MeaningMagnetic resonance imaging
Policy useUsed for baseline imaging before treatment initiation and for evaluating neurodegeneration or neuronal injury
PET
AbbreviationPET
MeaningPositron emission tomography
Policy useUsed for amyloid or tau imaging to document relevant biomarker findings
Leqembi IV:
The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, and follows the product-specific dosing schedule.
18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 10 mg/kg every 2 weeks for 18 months, then every 2 or 4 weeks
Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.
Leqembi Iqlik initial therapy
Leqembi Iqlik may be considered medically necessary when ALL of the drug-specific criteria are met.
Leqembi Iqlik: The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, receives 500 mg once every week, and meets the product-specific quantity limit.18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 500 mg once weekly; 8 or 4 autoinjectors per 28 days depending on strength
The quantity limit is 8 autoinjectors per 28 days for the 250 mg/1.25 mL autoinjector or 4 autoinjectors per 28 days for the 360 mg/1.5 mL autoinjector. Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.